Physician profile
Monte E Martin
NPI 1821138686
$14,683.26
in general payments reported to CMS, 2019-2025
73 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,597 · 2020: $1,127 · 2021: $1,448 · 2022: $2,160 · 2023: $2,102 · 2024: $2,604 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,067 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,066.92 |
| Education | $283.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $975.53 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $967.13 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $939.14 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $791.80 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Pfizer INC. | $762.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $671.19 | 2019-2025 | |
| Seagen INC. | $613.97 | 2019-2025 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $578.45 | 2019-2025 | Venclexta, Tecentriq, Lunsumio |
| Incyte Corporation | $541.59 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Amgen INC. | $502.07 | 2019-2023 | Lumakras |
| Genzyme Corporation | $485.28 | 2019-2025 | |
| Abbvie INC. | $412.36 | 2019-2025 | |
| Beigene USA, INC. | $380.97 | 2020-2023 | Brukinsa |
| Daiichi Sankyo INC. | $355.29 | 2021-2024 | Enhertu, Injectafer |
| Celgene Corporation | $338.32 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $337.21 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Regeneron Healthcare Solutions, INC. | $293.06 | 2019-2025 | Libtayo |
| Gilead Sciences, INC. | $276.50 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.46 | 2019-2025 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $228.77 | 2019-2023 | Rezlidhia, Tavalisse |
| Iovance Biotherapeutics, INC. | $196.28 | 2024 | Amtagvi |
| Lilly USA, LLC | $194.85 | 2019-2025 | Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $194.83 | 2019-2025 | Onivyde, Tazverik |
| Glaxosmithkline, LLC. | $193.53 | 2020-2025 | Ojjaara |
| Astellas Pharma US INC | $192.33 | 2019-2025 | Vyloy, Xtandi |
| Eisai INC. | $152.71 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $142.79 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $140.69 | 2020-2023 | Tepmetko, Bavencio |
| Jazz Pharmaceuticals INC. | $136.56 | 2020-2025 | Zepzelca |
| Bayer Healthcare Pharmaceuticals INC. | $128.93 | 2019-2025 | |
| Array Biopharma INC | $116.90 | 2021-2025 | Mektovi, Lorbrena, Braftovi |
| Clovis Oncology, INC. | $116.80 | 2019-2021 | |
| Kyowa Kirin, INC. | $111.09 | 2021-2024 | Poteligeo |
| Kite Pharma, INC. | $108.17 | 2020-2023 | |
| Adc Therapeutics America, INC. | $106.46 | 2022-2024 | |
| Puma Biotechnology, INC. | $98.48 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $94.00 | 2021-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $91.43 | 2021-2024 | Monoferric, Cosela |
| Foundation Medicine, INC. | $90.02 | 2019-2021 | |
| Sobi, INC | $89.21 | 2022-2024 | |
| Mirati Therapeutics, INC. | $79.10 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $77.04 | 2019-2023 | |
| Genmab U.S., INC. | $76.24 | 2023-2025 | Epkinly, Tivdak |
| Teva Pharmaceuticals USA, INC. | $70.59 | 2019-2020 | |
| Acceleron Pharma, INC. | $62.03 | 2020-2021 | |
| Cti Biopharma Corp. | $60.06 | 2022-2023 | Vonjo |
| Blueprint Medicines Corporation | $57.10 | 2023-2025 | Ayvakit |
| Adaptive Biotechnologies Corporation | $54.79 | 2022-2023 | Clonoseq |
| Coherus Oncology, INC. | $51.30 | 2024 | |
| Aveo Pharmaceuticals, INC. | $50.67 | 2022-2025 | |
| Stemline Therapeutics INC. | $44.51 | 2023-2024 | Orserdu |
| Beone Medicines USA, INC. | $41.82 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $38.50 | 2022-2024 | |
| Morphosys, US INC. | $38.13 | 2022-2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $37.80 | 2022-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $35.50 | 2021-2022 | |
| Verastem, INC. | $35.49 | 2019 | |
| Tesaro, INC. | $35.30 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $34.64 | 2022-2024 | Sancuso |
| Secura Bio, INC. | $33.89 | 2023-2024 | Copiktra |
| Caris Mpi, INC. | $32.79 | 2025 | Mi Cancer Seek |
| Springworks Therapeutics, INC. | $31.42 | 2024-2025 | Ogsiveo |
| Tempus Ai, INC | $29.40 | 2024 | |
| Pharmaessentia USA Corporation | $23.13 | 2025 | Besremi |
| Recordati_rare_diseases_inc. | $20.79 | 2025 | Enjaymo |
| G1 Therapeutics, INC. | $20.32 | 2023 | Cosela |
| Tersera Therapeutics LLC | $19.31 | 2022 | |
| Celltrion USA INC. | $19.29 | 2025 | Vegzelma |
| Fennec Pharmaceuticals, INC. | $18.37 | 2024 | Pedmark |
| Blue Earth Diagnostics | $17.08 | 2025 | Posluma |
| Dova Pharmaceuticals | $15.33 | 2020 | |
| Novocure INC. | $14.88 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
Keytruda $520Enhertu $321Darzalex $270Venclexta $232Libtayo $218Imbruvica $213Sarclisa $207Kisqali $203Amtagvi $196Opdivo $196Lynparza $194Brukinsa $194Epkinly $188Tukysa $167Ojjaara $160Tagrisso $155Fruzaqla $147Monjuvi $144Jakafi $132Erleada $124Reblozyl $119Tecvayli $106Trodelvy $103Adcetris $102Vonjo $101Ibrance $101Opdualag $99.32Padcev $97.99Pluvicto $95.76Xtandi $84.97Krazati $79.10Zynyz $77.87Talvey $74.55Lutathera $68.65Tecentriq $67.77Carvykti $65.62Ultomiris $64.48Verzenio $62.78Jaypirca $62.78Zepzelca $60.39Scemblix $59.26Cosela $57.22Ayvakit $57.10Onivyde $54.88Lenvima $54.52Udenyca $51.30Pemazyre $48.39Ninlaro $46.82Orserdu $44.51Poteligeo $41.45Vyloy $40.57Monoferric $40.18Fotivda $37.95Orgovyx $36.91Talzenna $36.91Inlyta $35.25Copiktra $33.89Mi Cancer Seek $32.79Tepmetko $32.19Ogsiveo $31.42Loqtorzi $29.34Gilotrif $28.18Mekinist $28.13Braftovi $27.67Lorbrena $27.67Mektovi $27.67Wayrilz $27.62Injectafer $27.36Lunsumio $27.10Pyrukynd $23.94Rybrevant $23.38Besremi $23.13Stivarga $22.78Nubeqa $22.78Yonsa $22.42Odomzo $22.42Clonoseq $22.34Welireg $21.98Lonsurf $21.57Inqovi $21.57Tivdak $21.53Keytruda Qlex $21.52Sancuso $21.51Nerlynx $21.36Enjaymo $20.79Lumakras $20.76Tecentriq Hybreza $20.56Phesgo $20.56Itovebi $20.56Oxbryta $20.35Fabhalta $20.00Vegzelma $19.29Tazverik $19.06Xalkori $18.79Polivy $18.41Pedmark $18.37Akeega $17.89Balversa $17.89Bavencio $17.41Pomalyst $17.33
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.